A5056064349- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Diet and metabolism studies
- Chronic Kidney Disease and Diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Neuroendocrine Tumor Research Advances
- Cardiovascular Function and Risk Factors
- Metabolism and Genetic Disorders
- Muscle metabolism and nutrition
- Helicobacter pylori-related gastroenterology studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pancreatitis Pathology and Treatment
- Blood Pressure and Hypertension Studies
- Adipose Tissue and Metabolism
- Pharmacology and Obesity Treatment
- Diabetes and associated disorders
- Clinical Nutrition and Gastroenterology
- Receptor Mechanisms and Signaling
- Chronic Lymphocytic Leukemia Research
- Hormonal Regulation and Hypertension
- Peptidase Inhibition and Analysis
- Glycogen Storage Diseases and Myoclonus
- HIV/AIDS drug development and treatment
Boehringer Ingelheim (Germany)
2011-2020
Universität Ulm
2018
Novo Nordisk (Denmark)
2018
Diabetes UK
2018
Manchester Academic Health Science Centre
2018
University of Manchester
2018
Boehringer Ingelheim (Taiwan)
2016
Ibero American University
2015
Bracknell and Wokingham College
2014
Boehringer Ingelheim (Canada)
2013
Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced major events in patients with type diabetes at high for We wanted to determine long-term effects analysis that was prespecified component secondary microvascular outcome trial.We randomly assigned estimated glomerular filtration rate least 30 ml per minute 1.73 m(2) body-surface area receive either empagliflozin (at...
Background— The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect 8 weeks’ sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects type 1 diabetes mellitus (T1D). Methods and Results— Inulin (glomerular filtration rate; GFR) paraaminohippurate (effective plasma flow) clearances were measured individuals based having (T1D-H, GFR ≥ 135 mL/min/1.73m , n=27) or normal (T1D-N, 90–134 n=13) at...
Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but included limited numbers patients high risk and chronic kidney disease.To evaluate the effect linagliptin, a selective DPP-4 inhibitor, on outcomes in type at events.Randomized, placebo-controlled, multicenter noninferiority trial conducted from August 2013 to 2016 605 clinic sites 27 countries among adults diabetes, hemoglobin A1c...
To determine the effects of empagliflozin on blood pressure (BP) and markers arterial stiffness vascular resistance in patients with type 2 diabetes mellitus (T2DM).We conducted a post hoc analysis data from phase III trial T2DM hypertension receiving 12 weeks' four trials 24 (cohort 1, n = 823; cohort 2, 2477). BP was measured using 24-h monitoring 1) or seated office measurements 2).Empagliflozin reduced systolic (SBP) diastolic both cohorts (p < 0.001 vs placebo), without increasing heart...
Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type diabetes mellitus established disease the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial Type Diabetes Mellitus Patients). Urinary glucose excretion empagliflozin decreases declining renal function, resulting less potency for lowering kidney disease. We investigated effects of on clinical outcomes mellitus, disease, chronic disease.Patients...
This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients with type 2 diabetes (T2DM).Patients HbA1c ≥7 ≤10% were randomized treated once daily 10 mg (n = 165), 25 168) or placebo 165) for 24 weeks. Endpoints included changes from baseline (primary endpoint), fasting plasma glucose (FPG) body weight at week 24.Adjusted mean standard error -0.6 0.07% -0.7 mg, respectively, vs. -0.1 (both p < 0.001). More ≥7% achieved <7% (23.8%)...
OBJECTIVE To investigate the efficacy and tolerability of empagliflozin as an add-on to metformin therapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Patients HbA1c levels ≥7% ≤ 10% (≥53 ≤86 mmol/mol) while receiving (≥1,500 mg/day) were randomized treated once-daily treatment 10 mg (n = 217), 25 213), or placebo 207) for 24 weeks. The primary end point was change level from baseline at week 24. Key secondary points changes weight mean daily glucose (MDG) RESULTS At 24,...
To investigate the efficacy and tolerability of empagliflozin as add-on to metformin sulfonylurea in patients with type 2 diabetes.
OBJECTIVE We investigated the efficacy and safety of sodium glucose cotransporter 2 inhibitor, empagliflozin, added to multiple daily injections insulin (MDI insulin) in obese patients with type diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS Patients inadequately controlled on MDI ± metformin (mean HbA1c 8.3% [67 mmol/mol]; BMI 34.8 kg/m2; dose 92 international units/day) were randomized treated once-daily empagliflozin 10 mg (n = 186), 25 189), or placebo 188) for 52 weeks. Insulin...
To assess the safety and efficacy of potent selective dipeptidyl peptidase-4 inhibitor linagliptin 5 mg when given for 24 weeks to patients with type 2 diabetes who were either treatment-naive or had received one oral antidiabetes drug (OAD).This multicentre, randomized, parallel group, phase III study compared treatment (5 once daily, n = 336) placebo (n 167) in patients. Before randomization, pretreated OAD underwent a washout period 6 weeks, which included run-in during last weeks....
Aim: To evaluate the efficacy and safety of potent selective dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin administered as add-on therapy to metformin in patients with type 2 diabetes inadequate glycaemic control. Methods: This 24-week, randomized, placebo-controlled, double-blind, parallel-group study was carried out 82 centres 10 countries. Patients HbA1c levels 7.0–10.0% on a maximum one additional antidiabetes medication, which discontinued at screening, continued ≥1500 mg/day for...
ABSTRACT Aim To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of empagliflozin in patients with type 2 diabetes following oral administration 10, 25 or 100 mg doses once daily over 28 days. Methods A total 78 were assigned to 10 (n = 16), 16) 30) placebo for Assessments included adverse events ( AE s) pharmacokinetic pharmacodynamic endpoints. Results Empagliflozin exposure increased dose‐proportionally dose range 10–100 showed linear respect time. Urinary...
Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) established CV disease (CVD) EMPA-REG OUTCOME® trial. We investigated whether benefit empagliflozin was observed across spectrum HF risk.Seven thousand twenty T2D (HbA1c 7-10% eGFR > 30 mL/min/1.73 m2) were treated 10 or 25 mg, placebo once daily followed for median 3.1 years. In without at baseline (89.9%), we derived 5-year incident using 9-variable...
OBJECTIVE—To compare the pathophysiology of impaired fasting glucose (IFG) and tolerance (IGT) in a more comprehensive standardized fashion than has hitherto been done. RESEARCH DESIGN AND METHODS—We studied 21 individuals with isolated IFG (IFG/normal [NGT]), 61 IGT (normal [NFG]/IGT), 240 healthy control subjects (NFG/NGT) by hyperglycemic clamps to determine first- second-phase insulin release sensitivity. Homeostasis model assessment (HOMA) indexes β-cell function (HOMA-%B) resistance...
To examine the efficacy and safety of dipeptidyl peptidase-4 inhibitor linagliptin in persons with Type 2 diabetes mellitus inadequately controlled [HbA(1c) 53-86 mmol/mol (7.0-10.0%)] by metformin sulphonylurea combination treatment.A multi-centre, 24-week, randomized, double-blind, parallel-group study 1058 patients comparing (5 mg once daily) placebo when added to plus sulphonylurea. The primary endpoint was change HbA(1c) after 24 weeks.At week 24, placebo-corrected adjusted mean from...
To examine the effect of aging on insulin secretion (first- and second-phase release) sensitivity in people with normal glucose tolerance (NGT) or impaired (IGT).First- were assessed hyperglycemic clamp experiments 266 individuals NGT 130 IGT, ranging age from approximately 20 to 70 years. Changes beta-cell function compared using disposition index adjust for differences sensitivity.As expected, both phases release reduced IGT (all P < 0.01). Insulin was not independently correlated either...
To investigate the long-term safety and efficacy of empagliflozin, a sodium glucose cotransporter 2 inhibitor; sitagliptin; metformin in patients with type diabetes.In this randomized, open-label, 78-week extension study two 12-week, blinded, dose-finding studies empagliflozin (monotherapy add-on to metformin) open-label comparators, 272 received 10 mg (166 as metformin), 275 25 56 metformin, sitagliptin metformin.Changes from baseline HbA1c at week 90 were -0.34 -0.63% (-3.7 -6.9 mmol/mol)...
Aim This Phase IIb , randomized, double‐blind, placebo‐controlled trial evaluated the efficacy, safety, tolerability and pharmacokinetics of empagliflozin in patients with type 2 diabetes. Methods Four hundred eight (treatment‐naïve or after a 4‐week wash‐out period) were randomized to receive 5, 10 25 mg once daily, placebo open‐label metformin for 12 weeks. The primary endpoint was change haemoglobin A1c ( HbA1c ) Results After weeks' treatment, showed dose‐dependent reductions from...
To evaluate the efficacy and safety of empagliflozin/linagliptin in subjects with type 2 diabetes.Subjects not receiving antidiabetes therapy for ≥12 weeks were randomized to empagliflozin 25 mg/linagliptin 5 mg (n = 137), 10 136), 135), 134), or linagliptin 135) 52 weeks. The primary end point was change from baseline HbA1c at week 24.Mean 7.99-8.05% (64 mmol/mol). At 24, adjusted mean (SE) changes mg, -1.08 (0.06)% (-11.8 [0.7] mmol/mol), -1.24 (-13.6 -0.95 (-10.4 -0.83 (-9.1 -0.67 (-7.3...